Solifenacin (Bispec (5 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...
Sept. 20, 2005 (Atlanta) — Results from the STAR trial, comparing two new-generation antimuscarinics solifenacin and tolterodine extended release (ER), suggest that solifenacin is superior in reducing ...
Antimuscarinics have remained the standard of care for patients with overactive bladder (OAB) syndrome for several decades, despite the fact that, owing to their adverse effects, these drugs are ...
The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Solifenacin (Soliten (10 mg)) is a urinary ...
The US Food and Drug Administration (FDA) has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate (Vesicare, Astellas Pharma) for the treatment of overactive ...
PARIS—Patients with severely bothersome overactive bladder (OAB) symptoms who have failed treatment with tolterodine ER may benefit by switching to solifenacin, research suggests. At the Société ...
Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...
Patients with chronic overactive bladder (OAB) are usually treated long-term with antimuscarinic agents. However, adherence to treatment is poor—rates as low as 20% at 1 year have been reported in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results